Curis (NASDAQ:CRIS) Downgraded to “Strong Sell” Rating by Zacks Research

Zacks Research downgraded shares of Curis (NASDAQ:CRIS) from a hold rating to a strong sell rating in a research report released on Tuesday morning,Zacks.com reports.

CRIS has been the subject of a number of other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $43.00 target price (up from $17.00) on shares of Curis in a research note on Friday, July 24th. Finally, Wall Street Zen lowered Curis to a “strong sell” rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $43.00.

Curis Stock Down 27.7%

NASDAQ:CRIS opened at $1.67 on Tuesday. Curis has a 52 week low of $1.63 and a 52 week high of $39.00. The stock has a market capitalization of $3.49 million, a PE ratio of -0.07 and a beta of 3.13. The stock’s 50-day moving average price is $6.15 and its 200-day moving average price is $11.93.

Curis (NASDAQ:CRIS) last released its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($25.00) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.53) by ($18.47). Sell-side analysts expect that Curis will post -33.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Curis

Large investors have recently bought and sold shares of the company. Jane Street Group LLC lifted its position in shares of Curis by 71.8% in the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 10,586 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Curis in the fourth quarter worth approximately $26,000. Focused Wealth Management Inc purchased a new stake in shares of Curis during the second quarter worth approximately $26,000. BlackRock Inc. purchased a new stake in shares of Curis during the second quarter worth approximately $28,000. Finally, Squarepoint Ops LLC raised its stake in Curis by 46.2% in the 4th quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 27,343 shares during the last quarter. 29.97% of the stock is currently owned by hedge funds and other institutional investors.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.